Abstract
PALB2 loss-of-function variants are associated with increased risk of breast and other cancers, but the clinical relevance of missense variants (MVs) remains uncertain. Recent findings reported by Wiltshire et al., Rodrigue et al., and Boonen et al. demonstrate that some MVs disrupt PALB2 function. This new information will support the clinical management of families who carry these MVs and inform their treatment.
Original language | English |
---|---|
Pages (from-to) | 263-265 |
Number of pages | 3 |
Journal | Trends In Cancer |
Volume | 6 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1 Apr 2020 |
Keywords
- cancer risk
- functional assays
- genetic testing
- missense variants
- PALB2